# US 10,307,458 B2 · Peptide as absorption enhancer and composition containing same > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,307,458 B2 - Document ID: US10307458B2 - Status: Granted - Kind: B2 - Application number: 15/323,055 - Filed: 2015-05-27 - Published: 2017-05-25 - Granted: 2019-06-04 - Earliest claimed: 2014-06-30 - Assignees: Soonchunhyang University Industry Academy Cooperation Foundation - Applicants: Soonchunhyang University Industry Academy Cooperation Foundation - Inventors: Keon-Hyoung Song - Web page: https://patentgrep.com/patent/US10307458B2 ## CPC - A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)} - A61K 9/0043: {Nose} - C07K 7/06: having 5 to 11 amino acids - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract As described herein, an peptide of SEQ ID NO: 1 is modified at the terminal end. Specifically, the carboxyl-group of the leucine at the terminal end of the amino acid sequence FCIGRL (SEQ ID NO: 1) is modified with a —CONH2. This modified peptide is used as a permeation enhancer to boost the mucous membrane permeation, thereby noticeably increasing the bioavailability of a drug that is administered together with the modified peptide. The drug to be administered with the modified peptide can be cyclosporine A. ## Claims ### Claim 1 A composition for enhancing mucous membrane permeability, the composition comprising an amino acid sequence FCIGRL (SEQ ID NO:1), wherein the carboxyl group (—COOH) of Leucine at the terminal end of the amino acid sequence is modified into —CONH2; and an active component, wherein the active component is not linked to the peptide. ### Claim 2 (depends on 1) The composition for enhancing mucous membrane permeability of claim 1, wherein the active component is cyclosporine A. ### Claim 3 (depends on 2) The composition for enhancing mucous membrane permeability of claim 2, wherein the composition further comprises a pharmaceutically acceptable additive or adjuvant. ### Claim 4 (depends on 1) The composition for enhancing membrane permeability of claim 1, wherein the mucous membrane is a mucous membrane with the expressed tight junction. ### Claim 5 (depends on 4) The composition for enhancing membrane permeability of claim 4, wherein the mucous membrane is a mucous membrane of small intestine, nasal cavity, oral cavity, skin, lung, vagina, rectum, or large intestine. ### Claim 6 A preparation comprising: a peptide having an amino acid sequence FCIGRL (SEQ ID NO:1), wherein the carboxyl group (—COOH) of Leucine at the terminal of the amino acid sequence is modified into —CONH2; and an active component, wherein the active component is cyclosporine A and is not linked to the peptide. ### Claim 7 (depends on 6) The preparation of claim 6, wherein the preparation is taken by oral, nasal, buccal, transdermal, transpulmorary, rectal, or vaginal administration. ### Claim 8 (depends on 6) The preparation of claim 6, wherein the preparation further comprises a pharmaceutically acceptable additive or adjuvant. ### Claim 9 (depends on 6) The preparation of claim 6, wherein the preparation is for enhancement of mucous membrane permeability. ### Claim 10 (depends on 6) The preparation of claim 6, wherein the preparation contains 0.001 to 50 wt % of the peptide. ### Claim 11 A method of enhancing permeation of an active component through mucous membranes in a subject comprising administering to a subject in need thereof an active component and a peptide respectively, wherein the peptide has an amino acid sequence FCIGRL (SEQ ID NO:1) wherein the carboxyl group (—COOH) of Leucine at the terminal end of the amino acid sequence is modified into —CONH2 and the peptide boosts the mucous membrane permeation of the active component, and the active component is a cyclosporine A and is not linked to the peptide. ### Claim 12 (depends on 11) The method of claim 11, wherein the mucous membrane is selected from a group consisting of a mucous membrane of small intestine, a mucous membrane of nasal cavity, a mucous membrane of oral cavity, a mucous membrane of skin, a mucous membrane of lung, a mucous membrane of vagina, a mucous membrane of rectum, and a mucous membrane of large intestine. ### Claim 13 (depends on 12) The method of claim 12, wherein the active component and peptide are in the form of a dosage form selected from the group consisting of a liquid, capsules, granules and tablets. ### Claim 14 (depends on 13) The method of claim 13, wherein the liquid dosage form is selected from the group consisting of an aqueous solution, suspension, and an emulsion. ### Claim 15 (depends on 11) The method of claim 11, wherein the peptide opens a tight junction between adjacent cells in the mucous membrane. ### Claim 16 (depends on 11) The method of claim 11, wherein the active component and the peptide are administered once a day or multiple times a day. ### Claim 17 (depends on 11) The method of claim 11, wherein the peptide is administered in an amount of 0.0001 mg/kg to 100 mg/kg. ### Claim 18 (depends on 13) The method of claim 13, wherein the dosage form further comprises a pharmaceutically acceptable additive or adjuvant.